Disparate Candida albicans Biofilm Formation in Clinical Lipid Emulsions Due to Capric Acid-Mediated Inhibition
Copyright © 2019 American Society for Microbiology..
Receipt of parenteral nutrition (PN) remains an independent risk factor for developing catheter-related bloodstream infections (CR-BSI) caused by fungi, including by the polymorphic fungus Candida albicans, which is notoriously adept at forming drug-resistant biofilm structures. Among a variety of macronutrients, PN solutions contain lipid emulsions to supply daily essential fats and are often delivered via central venous catheters (CVCs). Therefore, using an in vitro biofilm model system, we sought to determine whether various clinical lipid emulsions differentially impacted biofilm growth in C. albicans We observed that the lipid emulsions Intralipid and Omegaven both stimulated C. albicans biofilm formation during growth in minimal medium or a macronutrient PN solution. Conversely, Smoflipid inhibited C. albicans biofilm formation by approximately 50%. Follow-up studies revealed that while Smoflipid did not impair C. albicans growth, it did significantly inhibit hypha formation and hyphal elongation. Moreover, growth inhibition could be recapitulated in Intralipid when supplemented with capric acid-a fatty acid present in Smoflipid but absent in Intralipid. Capric acid was also found to dose dependently inhibit C. albicans biofilm formation in PN solutions. This is the first study to directly compare different clinical lipid emulsions for their capacity to affect C. albicans biofilm growth. Results derived from this study necessitate further research regarding different lipid emulsions and rates of fungus-associated CR-BSIs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 63(2019), 11 vom: 12. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Willems, Hubertine M E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.08.2020 Date Revised 20.01.2022 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1128/AAC.01394-19 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300163940 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300163940 | ||
| 003 | DE-627 | ||
| 005 | 20231225101926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/AAC.01394-19 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1000.xml |
| 035 | |a (DE-627)NLM300163940 | ||
| 035 | |a (NLM)31405860 | ||
| 035 | |a (PII)e01394-19 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Willems, Hubertine M E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Disparate Candida albicans Biofilm Formation in Clinical Lipid Emulsions Due to Capric Acid-Mediated Inhibition |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.08.2020 | ||
| 500 | |a Date Revised 20.01.2022 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 American Society for Microbiology. | ||
| 520 | |a Receipt of parenteral nutrition (PN) remains an independent risk factor for developing catheter-related bloodstream infections (CR-BSI) caused by fungi, including by the polymorphic fungus Candida albicans, which is notoriously adept at forming drug-resistant biofilm structures. Among a variety of macronutrients, PN solutions contain lipid emulsions to supply daily essential fats and are often delivered via central venous catheters (CVCs). Therefore, using an in vitro biofilm model system, we sought to determine whether various clinical lipid emulsions differentially impacted biofilm growth in C. albicans We observed that the lipid emulsions Intralipid and Omegaven both stimulated C. albicans biofilm formation during growth in minimal medium or a macronutrient PN solution. Conversely, Smoflipid inhibited C. albicans biofilm formation by approximately 50%. Follow-up studies revealed that while Smoflipid did not impair C. albicans growth, it did significantly inhibit hypha formation and hyphal elongation. Moreover, growth inhibition could be recapitulated in Intralipid when supplemented with capric acid-a fatty acid present in Smoflipid but absent in Intralipid. Capric acid was also found to dose dependently inhibit C. albicans biofilm formation in PN solutions. This is the first study to directly compare different clinical lipid emulsions for their capacity to affect C. albicans biofilm growth. Results derived from this study necessitate further research regarding different lipid emulsions and rates of fungus-associated CR-BSIs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Candida | |
| 650 | 4 | |a Candida albicans | |
| 650 | 4 | |a biofilm | |
| 650 | 4 | |a catheter | |
| 650 | 4 | |a fungi | |
| 650 | 4 | |a infection | |
| 650 | 4 | |a infection control | |
| 650 | 4 | |a lipid emulsions | |
| 650 | 4 | |a lipids | |
| 650 | 4 | |a parenteral nutrition | |
| 650 | 7 | |a Decanoic Acids |2 NLM | |
| 650 | 7 | |a Emulsions |2 NLM | |
| 650 | 7 | |a Fatty Acids |2 NLM | |
| 650 | 7 | |a Phospholipids |2 NLM | |
| 650 | 7 | |a soybean oil, phospholipid emulsion |2 NLM | |
| 650 | 7 | |a decanoic acid |2 NLM | |
| 650 | 7 | |a 4G9EDB6V73 |2 NLM | |
| 650 | 7 | |a Soybean Oil |2 NLM | |
| 650 | 7 | |a 8001-22-7 |2 NLM | |
| 700 | 1 | |a Stultz, Jeremy S |e verfasserin |4 aut | |
| 700 | 1 | |a Coltrane, Molly E |e verfasserin |4 aut | |
| 700 | 1 | |a Fortwendel, Jabez P |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, Brian M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 63(2019), 11 vom: 12. Nov. |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2019 |g number:11 |g day:12 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/AAC.01394-19 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2019 |e 11 |b 12 |c 11 | ||